Proteomic detection of cancer in asbestosis patients using SELDI-TOF discovered serum protein biomarkers.
Tooker-BC; Newman-LS; Bowler-RP; Karjalainen-A; Oksa-P; Vainio-H; Pukkala-E; Brandt-Rauf-PW
Biomarkers 2011 Mar; 16(2):181-191
OBJECTIVES: To identify biomarkers for cancer in asbestosis patients. METHODS: SELDI-TOF and CART were used to identify serum biomarker profiles in 35 asbestosis patients who subsequently developed cancer and 35 did not develop cancer. RESULTS: Three polypeptide peaks (5707.01, 6598.10, and 20,780.70 Da) could predict the development of cancer with 87 percent sensitivity and 70 percent specificity. The first two peaks were identified as KIF18A and KIF5A, respectively, and are part of the Kinesin Superfamily of proteins. CONCLUSIONS: We identified two Kinesin proteins that can be potentially used as blood biomarkers to identify asbestosis patients at risk of developing lung cancer.
Cancer; Biomarkers; Asbestosis; Blood-serum; Pathology; Disease-incidence; Peptides; Proteins; Lung; Lung-cancer; Risk-factors;
Author Keywords: Disease progression; CART analysis; serum
Brian C. Tooker, Division of Allergy and Clinical Immunology, University of Colorado Denver, Building: RC2, Mail Stop: B164, 12700 E. 19th Ave, Aurora, CO, 80045
University of Illinois